Table of Contents Author Guidelines Submit a Manuscript
Anemia
Volume 2015, Article ID 189404, 9 pages
http://dx.doi.org/10.1155/2015/189404
Research Article

The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients

1Research Team of Pharmacoepidemiology & Pharmacoeconomics, Medical and Pharmacy School, Mohammed V University, Madinat Al Irfane, 10000 Rabat, Morocco
2Department of Nephrology & Dialysis, Military Hospital Agadir, 20450 Agadir, Morocco
3Meknes Dialysis Center (on Behalf of Moroccan Society of Nephrology), 33150 Meknes, Morocco
4IdrissAlakbar Dialysis Center (on Behalf of the Scientific Committee, Moroccan Society of Nephrology), 12470 Rabat, Morocco

Received 2 October 2015; Accepted 6 December 2015

Academic Editor: Eitan Fibach

Copyright © 2015 Omar Maoujoud et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. McClellan, S. L. Aronoff, W. K. Bolton et al., “The prevalence of anemia in patients with chronic kidney disease,” Current Medical Research and Opinion, vol. 20, no. 9, pp. 1501–1510, 2004. View at Publisher · View at Google Scholar
  2. C.-Y. Hsu, “Epidemiology of anemia associated with chronic renal insufficiency,” Current Opinion in Nephrology and Hypertension, vol. 11, no. 3, pp. 337–341, 2002. View at Publisher · View at Google Scholar
  3. P. A. Marsden, “Treatment of anemia in chronic kidney disease—strategies based on evidence,” The New England Journal of Medicine, vol. 361, no. 21, pp. 2089–2090, 2009. View at Publisher · View at Google Scholar
  4. J. Jordan, J. Breckles, V. Leung, M. Hopkins, and M. Battistella, “Conversion from epoetin alfa to darbepoetin alfa: effects on patients' hemoglobin and costs to Canadian dialysis centres,” Canadian Journal of Hospital Pharmacy, vol. 65, no. 6, pp. 443–449, 2012. View at Google Scholar · View at Scopus
  5. R. W. Evans, B. Rader, and D. L. Manninen, “The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group,” The Journal of the American Medical Association, vol. 263, no. 6, pp. 825–830, 1990. View at Publisher · View at Google Scholar
  6. S. Li, R. N. Foley, and A. J. Collins, “Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States,” Kidney International, vol. 65, no. 5, pp. 1864–1869, 2004. View at Publisher · View at Google Scholar
  7. F. Locatelli, R. L. Pisoni, C. Combe et al., “Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS),” Nephrology Dialysis Transplantation, vol. 19, no. 1, pp. 121–132, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. H. C. Rayner, R. L. Pisoni, J. Bommer et al., “Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS),” Nephrology Dialysis Transplantation, vol. 19, no. 1, pp. 108–120, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. “References,” Kidney International Supplements, vol. 2, no. 4, pp. 331–335, 2012. View at Publisher · View at Google Scholar
  10. N. W. Levin, S. Fishbane, F. V. Cañedo et al., “Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA),” The Lancet, vol. 370, no. 9596, pp. 1415–1421, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. I. C. Macdougall, R. Walker, R. Provenzano et al., “C.E.R.A. Corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 2, pp. 337–347, 2008. View at Publisher · View at Google Scholar
  12. F. Dellanna, R. E. Winkler, F. Bozkurt et al., “Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study,” International Journal of Clinical Practice, vol. 65, no. 1, pp. 64–72, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. C. E. Halstenson, M. Macres, S. A. Katz et al., “Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta,” Clinical Pharmacology and Therapeutics, vol. 50, no. 6, pp. 702–712, 1991. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Schmid, “Cost-effectiveness of continuous erythropoietin receptor activator in anemia,” ClinicoEconomics and Outcomes Research, vol. 6, pp. 319–330, 2014. View at Publisher · View at Google Scholar
  15. I. C. Macdougall, R. Robson, S. Opatrna et al., “Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease,” Clinical Journal of the American Society of Nephrology, vol. 1, no. 6, pp. 1211–1215, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. SMN, Moroccan Society of Nephrology Guidelines RBMP. ALD 17(Insuffisance Renal Chronique Terminale), SMN, 2011.
  17. P. Gonzalez, E. Gomez, and J. Vargas, “PSY25 Renal Anemia (RA) treatment in Mexican public health care institutions: an evaluation of the costs and consequences,” Value in Health, vol. 12, no. 7, pp. A379–A380, 2009. View at Publisher · View at Google Scholar
  18. F. H. C. V. Silva, C. M. D. M. Vianna, and F. V. C. Silva, “PUK3 Cost-effectiveness of anemia treatment in dialysis patients in Brazil,” Value in Health, vol. 14, no. 7, p. A570, 2011. View at Publisher · View at Google Scholar
  19. D. Husereau, M. Drummond, S. Petrou et al., “Consolidated health economic evaluation reporting standards (CHEERS)—explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force,” Value in Health, vol. 16, no. 2, pp. 231–250, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Bezditko, L. Iakovlieva, O. Mishchenko, O. Gerasymova, and O. Kyrychenko, “PUK24 Pharmacoeconomic aspects of use of erythropoietin drugs in patients on hemodialysis in Ukraine,” Value in Health, vol. 15, no. 7, p. A459, 2012. View at Publisher · View at Google Scholar
  21. S. Franz, C. Jäger, and T. Gauthier, “Hemoglobin levels and development of ESA dose in hemodialysis patients after conversion to CERA: a multicenter observational study,” Swiss Medical Weekly, vol. 139, no. 45-46, supplement 178, p. 8S, 2009. View at Google Scholar
  22. M. D. Albero Molina, R. López-Menchero Martínez, C. del Pozo Fernández, L. Álvarez Fernández, and L. Sánchez Rodríguez, “Eficiencia de la administración mensual subcutánea de metoxi-polietilenglicol epoetina β (Mircera) en pacientes estables en hemodiálisis previamente tratados con eritropoyetinaEficiencia de la administración sc mensual de MIRCERA en pacientes en HD,” Diálisis y Trasplante, vol. 34, no. 3, pp. 93–100, 2013. View at Publisher · View at Google Scholar
  23. V. Escudero-Vilaplana, C. Martínez-Nieto, J. M. López-Gómez, A. Vega-Martínez, J. M. Bellón-Cano, and M. Sanjurjo-Sáez, “Erythropoiesis-stimulating agents in anaemia due to chronic kidney disease: a cost-minimization analysis,” International Journal of Clinical Pharmacy, vol. 35, no. 3, pp. 463–468, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Duman, A. Uyanik, A. Unsal et al., “Once-monthly continuous erythropoietin receptor activator (CERA) for haemoglobin maintenance in haemodialysis patients with chronic renal anaemia,” Clinical Kidney Journal, vol. 7, no. 5, pp. 464–469, 2014. View at Publisher · View at Google Scholar
  25. U. Saueressig, J. T. C. Kwan, E. De Cock, and C. Sapède, “Healthcare resource utilization for anemia management: current practice with erythropoiesis-stimulating agents and the impact of converting to once-monthly C.E.R.A.,” Blood Purification, vol. 26, no. 6, pp. 537–546, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. E. De Cock, F. Dellanna, K. Khellaf et al., “Time savings associated with C.E.R.A. once monthly: a time-and-motion study in hemodialysis centers in five European countries,” Journal of Medical Economics, vol. 16, no. 5, pp. 648–656, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. W. F. J. Klatko, “Time and motion study of anaemia management with erythropoiesis stimulating agents in haemodialysis units in Poland,” Journal of Health Policy and Outcomes Research, vol. 2, no. 1, pp. 126–132, 2013. View at Google Scholar
  28. N. W. Levin, “Quality of life and hematocrit level,” American Journal of Kidney Diseases, vol. 20, no. 1, supplement 1, pp. 16–20, 1992. View at Google Scholar
  29. M. Tonelli, W. C. Winkelmayer, K. K. Jindal, W. F. Owen Jr., and B. J. Manns, “The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients,” Kidney International, vol. 64, no. 1, pp. 295–304, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. F. M. Clement, S. Klarenbach, M. Tonelli, N. Wiebe, B. Hemmelgarn, and B. J. Manns, “An economic evaluation of erythropoiesis-stimulating agents in CKD,” American Journal of Kidney Diseases, vol. 56, no. 6, pp. 1050–1061, 2010. View at Publisher · View at Google Scholar · View at Scopus